World News

Unlike conventional pacemakers, which typically stimulate the right ventricle, CSP aims to activate the heart’s electrical conduction system more directly.

The acquisition gives Merck access to divesiran, an investigational small interfering RNA (siRNA) therapy for polycythemia vera (PV), a rare blood cancer characterised by excessive red blood cell production.

The Cios Go ID addresses these challenges with a compact design and an integrated touchscreen display that clinicians can position according to their needs.

Vir could also receive up to US$45 million in near-term preclinical milestone payments and up to US$1.74 billion in potential development, regulatory, and commercial milestones.

The agreement also includes US$35 million in preclinical milestone payments, with additional development and commercial milestones bringing the total potential deal value to nearly US$1.2 billion.

Pfizer will assume responsibility for subsequent clinical development, manufacturing, regulatory submissions and commercialisation after the discovery phase.

The firm secured capital from a broad investor base, including medical institutions, pension funds, family offices, sovereign wealth funds and university endowments.

Under the agreement, AstraZeneca will pay US$40 million upfront, with an additional US$1.46 billion available in development and commercial milestone payments.

CADDIE PLUS builds on the existing CADDIE system by adding real time polyp size classification and withdrawal time monitoring to help endoscopists assess lesions and monitor procedural quality.

The acquisition will enable Cotecna to serve pharmaceutical companies with a broader range of regulatory compliant testing services, while improving its capacity to respond to customer requirements across key markets.